Rimegepant
Nurtec Odt (rimegepant) is a small molecule pharmaceutical. Rimegepant was first approved as Nurtec Odt on 2020-02-27. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. The pharmaceutical is active against calcitonin gene-related peptide type 1 receptor. Nurtec odt's patents are valid until 2039-03-25 (FDA).
| Trade Name | Nurtec Odt |
|---|---|
| Common Name | Rimegepant |
| Indication | migraine disorders, migraine with aura, migraine without aura |
| Drug Class | Calcitonin gene-related peptide receptor antagonists |
